MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
9.22
+0.58 (6.71%)
At close: Apr 1, 2025, 4:00 PM
9.04
-0.18 (-1.99%)
After-hours: Apr 1, 2025, 7:56 PM EDT
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
36.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
INKT News
- 14 days ago - MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewsWire
- 4 weeks ago - MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewsWire
- 5 weeks ago - MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - GlobeNewsWire
- 6 weeks ago - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewsWire
- 3 months ago - MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewsWire
- 4 months ago - MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha